company background image
IMTX logo

Immatics NasdaqCM:IMTX Stock Report

Last Price

US$5.39

Market Cap

US$655.2m

7D

5.5%

1Y

-55.6%

Updated

02 Jun, 2025

Data

Company Financials +

Immatics N.V.

NasdaqCM:IMTX Stock Report

Market Cap: US$655.2m

IMTX Stock Overview

A clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. More details

IMTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 10.78% per year

Earnings have grown 26.2% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of 7.2% per year for the next 3 years

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Immatics N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Immatics
Historical stock prices
Current Share PriceUS$5.39
52 Week HighUS$13.77
52 Week LowUS$3.30
Beta0.87
1 Month Change3.06%
3 Month Change24.19%
1 Year Change-55.56%
3 Year Change-34.59%
5 Year Change-62.02%
Change since IPO-43.85%

Recent News & Updates

Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S

May 17
Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S

Recent updates

Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S

May 17
Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S

Immatics N.V.: Trading Below Cash, But Not Without Reason

Mar 28

Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price

Jan 12
Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price

Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Sep 21
Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

Jul 12
Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

May 03
Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Sep 26
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Jun 12
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics launches $110M stock offering

Oct 10

Cancer immunotherapy biotech Immatics up 18% on 4x normal volume

Jul 19

Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Jan 29
Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Dec 16
Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Apr 01
Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

Jan 18
What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

Shareholder Returns

IMTXUS BiotechsUS Market
7D5.5%0.1%1.7%
1Y-55.6%-13.1%11.5%

Return vs Industry: IMTX underperformed the US Biotechs industry which returned -13.1% over the past year.

Return vs Market: IMTX underperformed the US Market which returned 11.5% over the past year.

Price Volatility

Is IMTX's price volatile compared to industry and market?
IMTX volatility
IMTX Average Weekly Movement11.4%
Biotechs Industry Average Movement12.1%
Market Average Movement7.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market4.1%

Stable Share Price: IMTX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IMTX's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a646Harpreet Singhwww.immatics.com

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.

Immatics N.V. Fundamentals Summary

How do Immatics's earnings and revenue compare to its market cap?
IMTX fundamental statistics
Market capUS$655.16m
Earnings (TTM)-US$25.46m
Revenue (TTM)US$163.84m
4.0x
P/S Ratio
-25.7x
P/E Ratio

Is IMTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMTX income statement (TTM)
Revenue€144.15m
Cost of Revenue€157.88m
Gross Profit-€13.73m
Other Expenses€8.67m
Earnings-€22.40m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.18
Gross Margin-9.53%
Net Profit Margin-15.54%
Debt/Equity Ratio0%

How did IMTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/02 09:41
End of Day Share Price 2025/05/30 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immatics N.V. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Eric SchmidtCantor Fitzgerald & Co.
Yevgeniya LivshitsChardan Capital Markets, LLC